Picture of Taisho Pharmaceutical Holdings Co logo

4581 — Taisho Pharmaceutical Holdings Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Takeda preparing to sell Japan consumer health unit to Blackstone -Kyodo (updated)

(Adds company comment in fifth paragraph, details throughout)
    TOKYO, Aug 19 (Reuters) - Japan's Takeda Pharmaceutical Co
Ltd  4502.T  is making final arrangements to sell its domestic
over-the-counter (OTC) business to U.S. investment fund
Blackstone Group Inc  BX.N , Kyodo News reported on Wednesday.
    Takeda, Japan's largest pharma company, has been reducing
its OTC assets worldwide as it seeks to refocus its business and
reduce debt following its $59 billion acquisition of Shire.
    Blackstone was among final bidders for the OTC unit, Reuters
reported in June, along with Bain Capital, CVC Capital Partners
and Taisho Pharmaceutical Holdings Co Ltd  4581.T .  urn:newsml:reuters.com:*:nL4N2DW1JR
    Takeda is looking to sell Takeda Consumer Healthcare, known
for its Alinamin line of energy drinks, for more than 300
billion yen ($2.85 billion) by the end of the month, Kyodo
reported.
    A Takeda spokeswoman declined to comment to Reuters on the
report beyond saying it had not come from the company. A
Blackstone representative was not immediately available for
comment.
    The Shire acquisition, completed in January 2019, expanded
Takeda's drug pipeline and diversified its global sales, but
also left it heavily indebted. To reduce the debt, Takeda has
pledged to dispose of $10 billion worth of non-core assets.
 urn:newsml:reuters.com:*:nL3N2CC16R
    Takeda's shares rose 1.1% in Tokyo versus a 0.2% gain for
the broader market.

($1 = 105.2600 yen)

 (Reporting by Chris Gallagher, Rocky Swift and Junko Fujita in
Tokyo; Editing by Shri Navaratnam and Christopher Cushing)
 ((chris.gallagher@thomsonreuters.com;))

Recent news on Taisho Pharmaceutical Holdings Co

See all news